KRAS and lung carcinoma: Functionally, we demonstrate that Mcl-1 deletion impairs the development of Kras-driven tumour and that pharmacologic inhibition of MCL-1 in fully established Kras-mutated p53-deleted murine lung cancers slows tumour progression.